Switching FVIII products does not pose greater immune risk: Study
Switching to a different clotting factor VIII (FVIII) product was not linked to a greater risk of developing neutralizing antibodies…
Articles by Andrea Lobo, PhD
Bleeding injuries in sports are rare, but low clotting factors raise risk
Incidences of bleeding from playing sports are rare among people with hemophilia, and more likely to occur in those…
Similar quality-of-life problems reported by hem A and B patients
Despite preventive treatment, people with hemophilia A or B report lower quality of life, mainly due to poor joint…
MRI can detect subclinical joint bleeding in severe hemophilia A
MRI screening can identify subclinical joint bleeding in some patients with severe hemophilia A on preventive treatment, according to…
Expanding Hemlibra’s EU Approval for Moderate Hem A Recommended
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Hemlibra’s (emicizumab) approval be expanded…